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A B S T R A C T
Several 3′,5′-cyclic nucleotide phosphodiesterases (PDEs) have been validated as good drug targets for a large
variety of diseases. Trypanosoma brucei PDEB1 (TbrPDEB1) has been designated as a promising drug target for
the treatment of human African trypanosomiasis. Recently, the first class of selective nanomolar TbrPDEB1
inhibitors was obtained by targeting the parasite specific P-pocket. However, these biphenyl-substituted tetra-
hydrophthalazinone-based inhibitors did not show potent cellular activity against Trypanosoma brucei (T. brucei)
parasites, leaving room for further optimization. Herein, we report the discovery of a new class of potent
TbrPDEB1 inhibitors that display improved activities against T. brucei parasites. Exploring different linkers
between the reported tetrahydrophthalazinone core scaffold and the amide tail group resulted in the discovery of
alkynamide phthalazinones as new TbrPDEB1 inhibitors, which exhibit submicromolar activities versus T. brucei
parasites and no cytotoxicity to human MRC-5 cells. Elucidation of the crystal structure of alkynamide 8b (NPD-
048) bound to the catalytic domain of TbrPDEB1 shows a bidentate interaction with the key-residue Gln874 and
good directionality towards the P-pocket. Incubation of trypanosomes with alkynamide 8b results in an increase
of intracellular cAMP, validating a PDE-mediated effect in vitro and providing a new interesting compound series
for further studies towards selective TbrPDEB1 inhibitors with potent phenotypic activity.
1. Introduction
Human African trypanosomiasis (HAT), one of the neglected tro-
pical diseases (NTDs), is caused by two members of the trypanosoma-
tids family, i.e. Trypanosoma brucei (T.b.) rhodesiense and T.b. gam-
biense.1 This disease, also called African sleeping sickness, is fatal when
left untreated and can have a big socioeconomic effect on rural popu-
lations in sub-Saharan Africa.2 Although the disease was almost eradi-
cated mid-1960s by active screening programs, it re-emerged in the
1980s as a result of discontinued disease surveillance and control pro-
grams.2,3 Five drugs are commonly used for treatment of HAT, but all
have major disadvantages including subspecies selectivity, disease stage
selectivity, complex administration and toxicity.4–7 First-stage
treatments are generally not effective for the second-stage of the dis-
ease, while drugs for the second-stage of the disease are often toxic and
require complex administration protocols.2,4,8 Much of the HAT phar-
macopoeia is becoming redundant because of drug resistance, necessi-
tating new control strategies, including new drugs.6,9,10
Human 3′,5′-cyclic nucleotide phosphodiesterases (hPDEs) have
proven to be successful drug targets for a broad range of diseases, in-
cluding COPD,11,12 heart failure13 and erectile dysfunction.14 In 2007
Oberholzer et al. published T. brucei PDEs as potential new targets for
the treatment of HAT.15 The parasite genome encodes four different
class I PDE families, PDEA-D, and a simultaneous reduction in the ex-
pression of Trypanosoma brucei PDEB1 (TbrPDEB1) and TbrPDEB2 with
siRNA results in fatal cell cycle defects.15,16 Furthermore, it was shown
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that gene silencing by siRNA prevents parasitemia in mice, further
demonstrating the potential of TbrPDEB1 and TbrPDEB2 as a target for
drugs against HAT.15
Several reports have been published about potential starting points
for selective inhibitors of this class of parasitic proteins, albeit with
mixed results.17–24 De Koning et al. reported a potent nanomolar
TbrPDEB1 inhibitor (NPD-001, 1, Fig. 1), which displays very similar
anti-parasitic effects compared to cells treated with TbrPDEB1/2 siRNA,
specifically a fatal inability to complete the abscission phase of the cell
division.25 However, the phthalazinone-based scaffold was originally
developed as a human PDE4 (hPDE4) inhibitor,26,27 explaining why
NPD-001 and close analogues exhibit sub-nanomolar activities for
hPDE4.24,28 Such a strong PDE4 activity of TbrPDEB1 inhibitors is
disqualifying for a potential drug, as hPDE4 inhibition is associated
with unacceptable side effects (e.g. emesis, gastro-intestinal dis-
turbance, headache and immune suppression).24,29–31
Structural comparison between hPDE4 and TbrPDEB1 reveals the
presence of an additional parasite-specific pocket (P-pocket) near the
active site, which can be exploited to obtain selective TbrPDEB1 in-
hibitors.19,33 Although docking studies had predicted P-pocket occu-
pancy for 1,28 the recent elucidation of the X-ray structure of the li-
gand–protein complex shows the absence of P-pocket interactions by 1,
thereby explaining the lack of TbrPDEB1 selectivity over hPDE4.32
Recently, we reported the first class of selective TbrPDEB1 inhibitors by
rigidifying the catechol linker with a biphenyl system.32 The two most
potent and selective molecules (NPD-008 and NPD-039, 2 and 3 re-
spectively) are shown in Fig. 1. The co-crystal structures of 2 and 3
bound to the catalytic domain of TbrPDEB1 confirmed that the P-pocket
is indeed occupied by the glycinamide tail. Unfortunately, both com-
pounds show reduced phenotypic activity against T. brucei parasites in
vitro, halting their further development as anti-T. brucei agents and
indicating that improvement of the trypanocidal activity is desired.32
Herein, we describe the search and discovery of other rigidified
molecules based on the same phthalazinone scaffold as 2 and 3. This
new class of TbrPDEB1 inhibitors exhibits submicromolar potency
against T. brucei and induces a robust, dose-dependent increase in the
intracellular cAMP levels of bloodstream form trypanosomes, at con-
centrations similar to its trypanocidal IC50-value.
2. Results and discussion
2.1. Compound design and inhibitory activity against TbrPDEB1
Since targeting the P-pocket via the biphenyl linker resulted in the
expected selectivity of the phthalazinone-based inhibitors 2 and 3 for
TbrPDEB1 over hPDE4, further optimisation was started by installing
small groups on the biphenyl linker. However, the possibilities to
modify the benzamide ring seem very limited, since small changes in
size and electron density of the ring dramatically decrease the activity
against TbrPDEB1 (Table 1). The minor change of a proton (NPD-008,
2) to an ortho or meta fluorine (4a and 4d, respectively) substitution
already results in a decrease in potency by at least 0.9 log units. A larger
decrease in potency is observed for electron-donating substituents such
as methyl and methoxy groups on either position (4b, 4c, 4e and 4f).
Subtle differences in potency are observed between ortho- and meta-
substitutions, in favour of the modification on the meta-position. In
addition, the flexibility of the amide bond was reduced by in-
corporating an isoindole as linker in an attempt to force the substituents
to occupy the P-pocket (5a-c, Table 1). However, this too resulted in
a> 10-fold decrease in potency and adding an ether or amide tail
group to N1 (5b and 5c, respectively) did not improve activity either.
As increasing linker size did not improve potency, linker size reductions
were investigated. In view of the molecular weight, logP and aqueous so-
lubility of the molecules, it was decided to replace the cycloheptyl sub-
stituent of the phthalazinone scaffold with an isopropyl group for this series,
as this modification has been shown to yield a small positive effect on the
selectivity profile (compare 2 and 3, Fig. 1). In search for a bioisostere of the
phenyl group a thiophene ring was introduced as linker34, leading to dra-
matically reduced TbrPDEB1 activity (Table 2), with all thiophene com-
pounds (6a-e) showing at least a 100-fold reduction in TbrPDEB1 activity
compared to 3, including 6e, which represents a direct replacement of the
phenyl moiety of 3 with a thiophene. A similar effect was observed when
the phenyl ring was replaced by the non-aromatic azetidine group, as none
of the azetidines (7a-d) display activities below 10 µM.
The results indicate that the vector that defines the accessibility of
the P-pocket is not very tolerant to changes. To illustrate the differences
in addressing the P-pocket, the unsubstituted thiophene amide and
azetidine amide were docked in the crystal structure of TbrPDEB1 li-
gated with 2 (PDB id: 5G2B) using PLANTS. As illustrated in Fig. 2, a
subtle difference in directionality of the linker is observed for the
thiophene and azetidine linkers, when compared to 2. Both analogues
bend the carboxamide group towards the protein helix and interact
with the conserved residue Gln874, but the interaction seems un-
productive as the thiophene-linked amide is in close proximity of the
protein and most likely will sterically clash with it.
Therefore, new derivatives with an alkyne functionality were de-
signed that more closely obey the vector as defined by the phenyl-
substituent in 2. A reduction in TbrPDEB1 potency was observed for all
alkynamides when compared to 2 (Table 2).
However, modifying the terminal amide (NPD-048, 8b) with dif-
ferent tail groups gave, as seen with the phenyl linker,32 a small in-
crease in potency. More flexible tail groups such as a n-butyl (8c) or
furfuryl (8f) show a slightly higher activity (pKi= 6.4 ± 0.1 and
6.3 ± 0.01, respectively) when compared with the more rigid tail
groups such as morpholine (8e, pKi= 6.0 ± 0.1). Both observations
are in agreement with the previously observed SAR with the biphenyl
linker reported by Blaazer et al.32 In contrast to 2, the highest potency
in this new series of TbrPDEB1 inhibitors was not observed with a
glycinamide tail (8g), but with an n-butyl (8c) or furfuryl tail (8f).
Constraining the heteroatoms in an oxazole ring (8h) or absence of the
amide (8a) further reduced inhibitory activity, which could indicate an
important function for the amide functionality.
Fig. 1. Previously reported TbrPDEB1 inhibitors.25,28,32
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2.2. Biological evaluation
2.2.1. Selectivity alkynamides over hPDE4
To assess the selectivity of the alkynamides as inhibitors for
TbrPDEB1 over hPDE4, the inhibitory activity of the alkynamides on
hPDE4 was measured (Table 3). In contrast to the previously published
selective TbrPDEB1 inhibitor NPD-008 (2), the primary carboxamide
(8b) and the alkynamides 8c–8f do not display the desired selectivity
for inhibition for TbrPDEB1 over human PDE4 (Table 3). Only minor
differences in the selectivity index (SI) are observed (range −0.3–0.3).
Although the current set of alkynamides does not display the desired
selectivity over hPDE4, when compared to the reference inhibitor NPD-
001 (1) with a SI value of −0.8, the current alkynamide scaffold might
offer future options to optimize the selectivity profile via structure-
based design (vide infra).
2.2.2. Antitrypanosomal activity and cytotoxicity
As mentioned before, the biphenyls 2 or 3 show a reduced potency
against the parasite (T. brucei pIC50= 5.3 ± 0.2 and 5.2 ± 0.1, re-
spectively) when compared to the potency against TbrPDEB1
(pKi= 7.0 for both compounds) and an undesirably high cytotoxicity
profile for human cells.32 The alkynamides display submicromolar po-
tencies against TbrPDEB1 and were therefore tested for their anti-
trypanosomal activity on T. brucei parasites, with MRC-5 cells as control
for general cytotoxicity towards human cells. The anti-parasitic activity
of all the alkynamides was increased when compared to the corre-
sponding biphenyl class (Table 3). The primary carboxamide 8b (T.
brucei pIC50 6.0 ± 0.3) is 6-fold more potent than NPD-008, but the
cytotoxicity (MRC-5 pCC50= 5.0 ± 0.1) is also increased. Both 8c and
8f display an in vitro potency against T. brucei of 0.6 µM and are non-
toxic to human MRC-5 cells at the highest concentration used (64 µM),
resulting in an interesting phenotypic profile. Installing a glycinamide
tail (8g) led to an almost equipotent molecule with decreased anti-
trypanosomal activity and increased cytotoxicity (T. brucei pIC50
5.4 ± 0.01 and MRC-5 pCC50= 5.4 ± 0.02). N-Methoxyethyl-sub-
stituted alkynamide 8d was unexpectedly inactive on both cell lines for
unknown reasons.
2.2.3. Intracellular cAMP levels
As reported previously, TbrPDEB1 inhibitors such as 1 and 2 are
able to increase intracellular cAMP levels in T. brucei parasites,25,32 and
we sought to confirm that NPD-048 (8b) was likewise acting on the
parasite principally through inhibition of the T. brucei PDEs. Incubation
of T. brucei parasites with 3.2 µM and 8 µM of 8b resulted in highly
significant increases in intracellular cAMP levels when compared to
untreated control cells (19.8 pmol/5×106 cells (P < 0.01) and
311 pmol/5×106 cells (P < 0.001) vs. 6.66 pmol/5× 106 cells, re-
spectively).
2.3. Crystal structures
In order to investigate the binding mode of the alkynamides, we
determined the co-crystal structures of the TbrPDEB1 and hPDE4D
catalytic domains in complex with 8b, at 2.10 and 2.16 Å resolution,
respectively (Fig. 3A, B). The PDE inhibitor binds in an almost identical
manner to both catalytic sites, maintaining the key hydrophobic in-
teractions in the hydrophobic clamp region and a hydrogen bond in-
teraction with the conserved Gln874, all mediated through its anisole
moiety.
Furthermore, the carbonyl of the alkynamide creates a second hy-
drogen bond interaction with the conserved Gln874. The co-crystal
structures clearly show that the alkynamide inhibitor 8b engages
identically with both enzymes (Fig. 3C). Moreover, the inability of 8b
to reach the P-pocket explains its lack of selectivity towards TbrPDEB1.
The alignment of the binding pose of 8b with the binding pose of 2 in
TbrPDEB1 (Fig. 3D) shows that 8b adopts a binding mode which is
slightly rotated to facilitate the double interaction with Gln874, posi-
tioning the carboxamide in front of the P-pocket. This positioning
provides an interesting opportunity for optimization of the alkynamide
phthalazinone scaffold. Further exploration by extension of the tail
group to target the P-pocket is currently ongoing.
2.4. Synthesis
The racemic cis-cycloheptyl tetrahydrophthalazinone scaffold
(building block 9) was synthesized as described previously.27,28,32 De-
rivatives 4 and 5 were synthesized via two different synthetic path-
ways. Firstly, a Suzuki reaction of 9 with the corresponding phe-
nylboronic acid was performed to obtain carboxylic acid 10a and
methyl ester 10b, which was hydrolyzed to carboxylic acid 10c in
quantitative yield (Scheme 1). The glycinamide tail was introduced by
an amide coupling using EDC/HOAt to afford 4b and 4d. Secondly,
building block 9 was converted to pinacol boronate ester 11 in mod-
erate yield and a subsequent Suzuki reaction with the corresponding
Table 1
Structure-activity relationship of substituted benzamide phthalazinones as TbrPDEB1 inhibitors.
# NPD- R pKi (mean ± S.E.M.)a # NPD- R pKi (mean ± S.E.M.)a
2 008 H 7.0b 5a 051 H 5.8 ± 0.03
4a 932 2-F 5.7 ± 0.1 5b 056 CH2CH2OMe 5.9 ± 0.1
4b 948 2-Me <5.0 5c 052 CH2CONH2 5.9 ± 0.01
4c 929 2-OMe 5.1 ± 0.1c
4d 945 3-F 6.1 ± 0.1
4e 931 3-Me 5.7 ± 0.1
4f 930 3-OMe 5.2 ± 0.1c
a Mean and S.E.M. values of at least 3 independent experiments.
b Reported value.32
c No full dose response curve obtained.
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arylbromide 12a-d (synthesized from the corresponding 4-bromo-
benzoic acid and glycinamide using EDC/HOAt) led to the desired
compounds 4a, 4c, 4e and 4f. Isoindolinones (5a-c) were synthesized
using a Suzuki reaction followed by an alkylation using the corre-
sponding alkyl bromide (Scheme 1).
Incorporation of the alkyne functionality to carboxylic acid 13 could
be achieved in a Sonogashira reaction of propiolic acid with 9 (Scheme
Table 2
Structure-activity relationship of phthalazinones with reduced linker size against TbrPDEB1.
# NPD- R pKi (mean ± S.E.M.)a # NPD- R pKi (mean ± S.E.M.)a
2 008 – 7.0b 8a 064 H 5.4 ± 0.1c
3 039 – 7.0b 8b 048 6.2 ± 0.02
6a 1030 5.0 ± 0.06c 8c 055 6.4 ± 0.02
6b 1027 <5.0 8d 050 6.1 ± 0.1
6c 092 <5.0 8e 054 6.0 ± 0.1
6d 1029 <5.0 8f 053 6.3 ± 0.01
6e 1028 <5.0 8g 046 6.2 ± 0.1
7a 1259 <5.0 8h 065 <5.0
7b 1256 <5.0
7c 1258 <5.0
7d 1257 <5.0
a Mean and S.E.M. values of at least 3 independent experiments.
b Reported values.32
c No full dose response curve obtained.
Fig. 2. Binding prediction of the phthalazinones with a thiophene amide (or-
ange) and azetidine amide (green) linker superposed on the X-ray structure of 2
(cyan) co-crystallized in the catalytic domain of TbrPDEB1 (modelled using the
PLANTS software package). Key residues, active site water molecules and me-
tals are shown for clarity. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
Table 3
Selectivity data for the synthesized alkynamides and their phenotypical activ-
ities (mean ± S.E.M).
pKi-value
# TbrPDEB1 hPDE4 ΔpKi T. brucei (pIC50) MRC-5 (pCC50)
2 7.0a 6.0a 1.0 5.3 ± 0.2a 4.4a
3 7.0a 5.7a 1.3 5.2 ± 0.1a 4.5a
8b 6.2 ± 0.02 6.5 ± 0.2 −0.3 6.0 ± 0.3 5.0 ± 0.1
8c 6.4 ± 0.02 6.2 ± 0.2 0.2 6.2 ± 0.3 < 4.2
8d 6.1 ± 0.1 5.8 ± 0.3 0.3 < 4.2 < 4.2
8f 6.3 ± 0.01 6.4 ± 0.1 −0.1 6.2 ± 0.1 4.3 ± 0.2
8g 6.2 ± 0.1 ND – 5.4 ± 0.01 5.4 ± 0.02
a Reported values.32
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2). However, since 13 was found to slowly degrade over time, it was
decided to use the crude material in a subsequent reaction with glyci-
namide to obtain 8g, albeit in an extremely low yield. An alternative
route towards the alkynamides avoiding the unstable carboxylic acid 13
involved synthesizing methyl ester 14 from pinacol boronate 11
(Scheme 1) in moderate yield, followed by an amidation in absence (for
8b) or presence (for 8c-f) of the Lewis acid trimethylaluminium. Un-
fortunately, synthesis of alkynamide 8g was unsuccessful using this
procedure. The primary alkyne 8a was synthesized via a Sonogashira
reaction with TMS-acetylene followed by deprotection of 15 with
NaOH, both in high yield. The resulting alkyne in 8a was converted into
aldehyde 16 and used subsequently in the Van Leusen oxazole synthesis
to obtain 8h.
The racemic cis-isopropyl tetrahydrophthalazinone building block
(17) was synthesized using the same procedure as described previously.
Building block 17 was used in a Suzuki reaction using 5-
Fig. 3. A) X-ray structure of 8b in TbrPDEB1
(PDB id: 6FTM) and B) hPDE4D (PDB id:
6FTW). A molecular surface of the P-pocket
region in TbrPDEB1 (grey) and hPDE4D
(purple) is displayed to highlight the struc-
tural differences between both enzymes. C)
Overlay of 8b in TbrPDEB1 (blue) and
hPDE4D (dark yellow). D) Overlay of 8b and
NPD-008 (2) in TbrPDEB1. Key residues for
interaction with the substrate are shown and
active site water molecules are shown as red
spheres. Binding site metals zinc and mag-
nesium are displayed as grey and magenta
spheres, respectively. (For interpretation of
the references to colour in this figure legend,
the reader is referred to the web version of
this article.)
Scheme 1. Reagents and conditions: a) corresponding boronic acid, PdCl2(dppf), Na2CO3, DME, H2O, 100 °C, 5 h, 10a: 46%, 10b: 39%; b) NaOH, THF, MeOH, 50 °C,
16 h, 98%; c) For 4b and 4d: glycinamide.HCl, EDC.HCl, HOAt, Et3N, DCM, rt, 1 h, 4b: 83%, 4d: 23%; d) Bis(pinacolato)diboron, PdCl2(dppf), KOAc, dioxane, reflux,
2.5 h, 28%; e) glycinamide.HCl, EDC.HCl, HOAt, Et3N, DCM, rt, overnight, 47–59%; f) For 4a, 4c, 4e and 4f: corresponding bromide, PdCl2(dppf), Na2CO3, DME,
H2O, 100 °C, 5 h, 27–57%; g) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one, PdCl2(dppf), Na2CO3, DME, H2O, 100 °C, 5 h, 73%; h) 1) NaH, DMF, rt,
30min; 2) R-Br, rt, 1.5 h, 14–27%.
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boronothiophene-2-carboxylic acid, followed by an amide coupling to
obtain 6a-e (Scheme 3). The azetidine linker was introduced using a
Buchwald-Hartwig cross coupling reaction with 3-cyanoazetidine to
obtain nitrile 19. The nitrile was hydrolyzed using NaOH and the
formed carboxylic acid 20 was coupled to various amines using EDC/
HOBt to obtain azetidines 7a-d.
3. Conclusion
A class of tetrahydrophthalazinone-based TbrPDEB1 inhibitors with
an alkynamide linker was identified as potent TbrPDEB1 inhibitors with
good potency against T. brucei parasites and an interesting cytotoxicity
profile. Alkynamide 8c (NPD-055) inhibits TbrPDEB1 in vitro, shows a
Scheme 2. Reagents and conditions: a) Propiolic acid, Pd(PPh3)2Cl2, dppb, DBU, DMSO, 50 °C, 15 h, used crude; b) For 8g: glycinamide.HCl, EDC.HCl, HOAt, Et3N,
DCM, rt, 30 h, 1% over 2 steps; c) Methyl propiolate, Pd(OAc)2, K2CO3, AgO, 70 °C, 3 h, 53%; d) For 8b: NH3, MeOH, rt, 2 h, 89%; e) For 8c-8f: corresponding amine,
AlMe3, PhMe, 50 °C, 1 d, 16–37%; f) Ethynyltrimethylsilane, Pd(PPh3)2Cl2, CuI, TEA, 80 °C, 3 h, 80%; g) NaOH, MeOH, H2O, rt, 2 h, 91% yield; h) 1) n-BuLi, THF,
−78 °C, 30min, 2) DMF, −78 °C, 1.5 h, 69%; i) 1-((isocyanomethyl)sulfonyl)-4-methylbenzene, K2CO3, MeOH, reflux, 1.5 h, 47%.
Scheme 3. Reagents and conditions: a) 5-boronothiophene-2-carboxylic acid, PdCl2(dppf), Na2CO3, DME, H2O, reflux, 5 h, 73%; b) Corresponding amine, EDC.HCl,
HOBt, Et3N, DCM, rt, 1 d, 15–76% yield; c) azetidine-3-carbonitrile.HCl, Cs2CO3, Pd(OAc)2, XPhos, PhMe, 100 °C, 3 d, 46%; d) NaOH, H2O, EtOH, 75 °C, 1 d, 47%; e)
corresponding amine, EDC.HCl, HOBt, Et3N, DCM, rt, 1 d, 31–70%.
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submicromolar trypanocidal activity (IC50= 0.6 µM) against T. brucei
parasites and displays no cytotoxicity versus human MRC-5 cells
(CC50 > 64 µM). The alkynamide 8b (NPD-048) was co-crystallized in
the catalytic domain of TbrPDEB1, showing a bidentate interaction of
8b with the key residue Gln874 in the active site. Moreover, this bi-
dentate interaction positions the carboxamide of 8b in close proximity
to the P-pocket of TbrPDEB1. The alkynamide 8b is able to raise in-
tracellular cAMP levels in living T. brucei parasites, supporting a PDE-
mediated mode of action in vitro.
4. Experimental
4.1. Protein production
Cloning, expression and purification of recombinant TbrPDEB1 and
hPDE4D catalytic domains were performed as previously described.32
4.2. Crystallisation, data collection and structure determination of inhibitor
complexes
TbrPDEB1 and hPDE4D catalytic domain crystals were grown in 24
well XRL plates (Molecular Dimensions) by vapor diffusion hanging
drop technique, typically maintaining a protein to crystallisation solu-
tion ratio of 1:1 and a reservoir volume of 500 μL. Crystals of TbrPDEB1
were obtained in a condition containing 20% PEG 3350, 400mM so-
dium formate, 300mM guanidine and 100mM MES pH 6.5 at 4 °C and
were complexed with NPD-048 by soaking in the crystal growth solu-
tion containing 15mM of the inhibitor for a period of 48 h. The soaked
crystals were then cryo protected, mounted on CryoLoop (Hampton
Research) or LithoLoops (Molecular Dimensions) and vitrified in liquid
nitrogen for data collection.
Crystals of hPDE4D catalytic domain were obtained in a condition
containing 24% PEG 3350, 30% ethylene glycol and 100mM HEPES pH
7.5 at 19 °C. Crystals were soaked with NPD-048 and archived in a way
similar to that of TbrPDEB1.
X-ray diffraction data were collected at Diamond Light Source
(Didcot, Oxfordshire, UK) beam lines I04 and I04-1 at 100 K using
Pilatus 6M-F detector (Dectris, Baden, Switzerland) and were processed
with XIA2 pipeline,35 which incorporates XDS36 and AIMLESS,37 or
were integrated using iMOSFLM38 and reduced using POINTLESS,
AIMLESS and TRUNCATE, all of which are part of CCP4.39
Structure of TbrPDEB1 and hPDE4D complexes with NPD-048 were
determined by molecular replacement using CCP4 suite program
PHASER40 that utilised respective apo models (TbrPDEB1, PDB id: 4I15;
hPDE4D, PDB id: 3SL3) as search templates. Stereochemical description
of NPD-048 was generated by ACEDRG available within the CCP4
package39 and ligand fitting and model adjustment were carried out in
COOT41 followed by maximum likelihood refinement with REFMAC42.
Data processing and refinement statistics are given in Table 4. Struc-
tural figures were prepared with PYMOL.43 Coordinates of the struc-
tures have been deposited to the RCSB Protein Data Bank with fol-
lowing accession codes: 6FTM (TbrPDEB1–NPD-048) and 6FTW
(hPDE4D–NPD-048).
4.2.1. Accession codes
The coordinates of the crystal structures have been deposited to the
RCSB Protein Data Bank under the following accession codes: 6FTM
(TbrPDEB1–NPD-048); 6FTW (hPDE4D–NPD-048); The authors will
release the atomic coordinates and experimental data upon article
publication.
4.3. Phosphodiesterase activity assays
The PDELight™ HTS cAMP phosphodiesterase Kit (Lonza,
Walkersville, USA) was used. The assay was performed at 25 °C in non-
binding, low volume 384 wells plates (Corning, Kennebunk, ME, USA).
PDE activity measurements (TbrPDEB1_CD; Km 3.45 µM, hPDE4B_CD;
Km 13.89 µM) were made in ‘stimulation buffer’ (50mM Hepes,
100mM NaCl, 10mM MgCl, 0.5mM EDTA, 0.05mg/mL BSA, pH 7.5).
Single concentration measurements were made at 10 µM inhibitor
concentration (triplo measurements/assay, n= 2). Dose response
curves were made in the range 100 µM–10 pM (triplo measurements/
assay, n=3). Compounds were diluted in DMSO (final concentration
1%). Inhibitor dilutions (2.5 µL) were transferred to the 384 wells plate,
2.5 µL PDE in stimulation buffer was added and mixed, 5 µL cAMP (at
2×Km up to 20 µM) is added and the assay mixture was incubated for
20min at 300 rpm. The reaction was terminated by addition of 5 µL
Lonza Stop Buffer supplemented with 10 µM NPD-001. Then 5 µL of
Lonza Detection reagent (diluted to 80% with reaction buffer) was
added and the reaction incubated for 10min at 300 rpm. Luminescence
was read with a Victor3 luminometer using a 0.1 s/well program.
RLUs were measured in comparison to the DMSO-only control, NPD-
001 always was taken along as positive control as a PDE inhibitor. The
Ki values of the inhibitors analyzed are represented as the mean of at
least three independent experiments with the associated standard error
of the mean (S.E.M.) as indicated. Due to solubility issues, we were not
able to determine full dose response curves for all compounds; Ki values
for such inhibitors were obtained by curve fitting (Graphpad Prism 7.0)
and the assumption of full inhibition to a level of inhibition by NPD-
001.
4.4. Phenotypic cellular assays
For the cellular assays, the following reference drugs were used as
positive controls: suramin (Sigma-Aldrich, Germany) for T. brucei
Table 4
Data collection and refinement statistics for NPD-048 bound TbrPDEB1 and
hPDE4D catalytic domain crystals.
TbrPDEB1 hPDE4D
Data collection
Space group C 1 2 1 P 21 21 21
Molecule/a.s.u 2 4
Cell dimensions a, b, c (Å) 149.05, 114.73,
63.80
99.14, 111.43,
160.06
α,β,γ(°) 90, 109.43, 90 90, 90, 90
Resolution (Å) 70.28–2.10
(2.16–2.10)*
65.00–2.16
(2.22–2.16)
Rmerge 0.103 (0.475) 0.085 (1.063)
I/σI 7.1 (2.3) 14.5 (1.7)
CC(1/2) 0.992 (0.603) 0.999 (0.623)
Completeness (%) 99.8 (99.9) 99.9 (99.8)
Redundancy 3.1 (2.8) 6.7 (6.6)
Refinement
Resolution (Å) 2.10 2.16
No. reflections 55,845 (4137) 90,714 (6591)
Rwork/Rfree 0.157/0.198 0.182/0.233
No. atoms
Protein 5272 10,561
Ligand 62 124
Water 327 551
B-factors
Protein 31.85 48.37
Ligand 37.11 59.31
Water 39.96 47.36
R.m.s. deviations
Bond lengths
(Å)
0.019 0.017
Bond angles
(°)
1.834 1.761
PDB accession no. 6FTM 6FTW
PDB ligand code E6Z E6Z
Data were collected from one crystal in each case.
* Values in parentheses are for highest-resolution shell.
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(pIC50= 7.4 ± 0.2, n=5), and tamoxifen (Sigma-Aldrich, Germany)
for MRC-5 cells (pIC50= 5.0 ± 0.1, n= 5). All compounds were tested
at five concentrations (64, 16, 4, 1 and 0.25 µM) to establish a full dose-
titration and determination of the IC50 and CC50, data are represented
as the mean of duplicate experiments ± S.E.M. The final concentration
of DMSO did not exceed 0.5% in the assays.
Antitrypanosomal cellular assay. T.b. brucei Squib-427 strain (sur-
amin-sensitive) was cultured at 37 °C and 5% CO2 in HMI-9 medium,
supplemented with 10% fetal calf serum (FCS). Approximately
1.5×104 trypomastigotes were added to each well and parasite growth
was assessed after 72 h at 37 °C by adding resazurin. Viability was as-
sessed fluorimetrically 24 h after the addition of resazurin. Fluorescence
was measured (excitation 550 nm, emission 590 nm) and the results
were expressed as percentage reduction in viability compared to con-
trol.
MRC-5 cytotoxicity cellular assay. MRC-5 SV2 cells, originally from
a human diploid lung cell line, were cultivated in MEM, supplemented
with L-glutamine (20mM), 16.5mM sodium hydrogen carbonate and
5% FCS. For the assay, 104 MRC-5 cells/well were seeded onto the test
plates containing the pre-diluted sample and incubated at 37 °C and 5%
CO2 for 72 h. Cell viability was assessed fluorimetrically 4 h after the of
addition of resazurin. Fluorescence was measured (excitation 550 nm,
emission 590 nm) and the results were expressed as percentage reduc-
tion in cell viability compared to control.
4.5. Intracellular cAMP assay
Quantification of intracellular cAMP was performed exactly as de-
scribed previously, using the Direct Cyclic AMP Enzyme Immunoassay
kit (Assay Designs).25 Briefly, bloodstreams form trypanosomes were
seeded at a density of 2×106 cells/mL in the log phase and incubated
at 37 °C and 5% CO2 overnight followed by incubation with or without
(negative control) potential PDE inhibitors at 2× and 5× IC50-values.
After 4 h, 5×106 cells/mL were counted for both treated and control,
transferred to microfuge tubes and centrifuged at 2000g for 10min at
4 °C in a Heraeus Biofuge centrifuge. The cell pellet was resuspended in
100 µL 0.1M hydrochloric acid, placed on ice for 20min, followed by
centrifugation at 12,000 rpm for 10min. The supernatant was stored at
−20 °C until assayed in duplicate using the Assays Design immunoassay
kit, following the manufacturer’s instructions. All experiments were
performed at least three times independently.
4.6. Chemistry
4.6.1. General
All reagents and solvents were obtained from commercial suppliers
and were used as received. All reactions were magnetically stirred and
carried out under an inert atmosphere. Reaction progress was mon-
itored using thin-layer chromatography (TLC) and LC-MS analysis. LC-
MS analysis was performed on a Shimadzu LC-20AD liquid chromato-
graph pump system, equipped with an Xbridge (C18) 5 µm column
(50mm, 4.6mm), connected to a Shimadzu SPD-M20A diode array
detector, and MS detection using a Shimadzu LC-MS-2010EV mass
spectrometer. The LC-MS conditions were as follows: solvent A (water
with 0.1% formic acid) and solvent B (MeCN with 0.1% formic acid),
flow rate of 1.0mL/min, start 5% B, linear gradient to 90% B in
4.5 min, then 1.5 min at 90% B, then linear gradient to 5% B in 0.5 min,
then 1.5min at 5% B; total run time of 8min. Silica gel column chro-
matography was carried out with automatic purification systems using
the indicated eluent. Reversed phase column purification was per-
formed on Grace Davison iES system with C18 cartridges (60 Å, 40 μm)
using the indicated eluent. Nuclear magnetic resonance (NMR) spectra
were recorded as indicated on a Bruker Avance 500 (500MHz for 1H
and 125.8MHz for 13C) instrument equipped with a Bruker
CryoPlatform, or on a Bruker DMX300 (300MHz for 1H) or a Bruker
Biospin (400MHz for 1H). Chemical shifts (δ in ppm) and coupling
constants (J in Hz) are reported with residual solvent as internal stan-
dard (δ 1H NMR: CDCl3 7.26; DMSO-d6 2.50; δ 13C NMR: CDCl3 77.16;
DMSO-d6 39.52). Abbreviations used for 1H NMR descriptions are as
follows: s= singlet, d= doublet, t= triplet, q= quintet, hept= heptet
dd= doublet of doublets, dt= doublet of triplets, tt = triplet of tri-
plets, m=multiplet, app d= apparent doublet, br= broad signal.
Exact mass measurements (HRMS) were performed on a Bruker
micrOTOF-Q instrument with electrospray ionization (ESI) in positive
ion mode and a capillary potential of 4500 V. Microwave reactions were
carried out in a Biotage Initiator+ using sealed microwave vials.
Systematic names for molecules were generated with ChemBioDraw
Ultra 14.0.0.117 (PerkinElmer, Inc.). The reported yields refer to iso-
lated pure products and are not optimized. The purity, reported as the
LC peak area % at 254 nm, of all final compounds was ≥95% based on
LC-MS. All compounds are isolated as a racemic mixture of cis-en-
antiomers.
4.6.2. Synthetic procedures
Building block 9 and 17 were prepared as described else-
where.27,28,32 All other compounds were prepared as described below.
4.6.2.1. 5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-1-
yl)-3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carboxylic acid (10a). To an
argon purged solution of 9 (0.50 g, 1.7mmol) and methyl 2-fluoro-4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (0.40 g, 2.0mmol)
in DME (8mL) was added aq. Na2CO3 (1.7M, 2.0mL) and PdCl2(dppf)
(53mg, 60 µmol). The reaction mixture was stirred and heated by
microwave irradiation at 100 °C for 1 h. The reaction mixture was
diluted with water (20mL) and washed with EtOAc (60mL). The
aqueous phase was acidified to ∼pH 1 with aq. HCl and extracted with
EtOAc (3×50mL). The combined organic phases were washed with
water (40mL), brine (40mL), dried over Na2SO4, filtered and
concentrated. The residue was purified on a reverse phase silica gel
column eluting with MeCN/H2O+0.1% formic acid (gradient, 5–95%) to
afford 10a as a yellow solid (268mg, 46%).
1H NMR (300MHz, CDCl3): δ 8.09 (t, J=8.1 Hz, 1H), 7.88–7.81
(m, 1H), 7.77 (s, 1H), 7.47–7.36 (m, 2H), 7.07 (d, J=8.7 Hz, 1H),
5.84–5.63 (m, 2H), 4.89–4.75 (m, 1H), 3.89 (s, 3H), 3.39–3.25 (m, 1H),
3.09–2.95 (m, 1H), 2.75 (t, J=5.4 Hz, 1H), 2.29–1.39 (m, 15H).
4.6.2.2. Methyl 5′-(cis-3-cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydro-
phthalazin-1-yl)-2′-methoxy-2-methyl-[1,1′-biphenyl]-4-carboxylate
(10b). This compound was prepared from 9 (500mg, 1.16mmol) and
methyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
benzoate (384mg, 1.39mmol) as described for 10a. The title
compound was obtained as a white solid (228mg, 39%).
1H NMR (300MHz, CDCl3): δ 7.96–7.90 (m, 2H), 7.86 (dd,
J=8.7 Hz, 2.4 Hz, 1H), 7.56 (d, J=2.4 Hz, 1H), 7.29 (d, J=7.8 Hz,
1H), 7.03 (d, J=8.7 Hz, 1H), 5.81–5.61 (m, 2H), 4.85–4.74 (m, 1H),
3.93 (s, 3H), 3.81 (s, 3H), 3.33–3.23 (m, 1H), 3.06–2.95 (m, 1H), 2.73
(t, J=6.0 Hz, 1H), 2.20 (s, 3H), 2.18–1.41 (m, 15H).
4.6.2.3. 5′-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2′-methoxy-2-methyl-[1,1′-biphenyl]-4-carboxylic acid (10c). To a
solution of 10b (228mg, 0.46mmol) in MeOH (5mL) and THF (12mL)
was added an aqueous solution of NaOH (2.0M, 3.6mL) and the
reaction mixture was stirred overnight at 50 °C. The reaction mixture
was cooled to rt, acidified with aq. HCl (4M) and extracted with EtOAc
(3×20mL). The combined organic phases were washed with water
(15mL), brine (15mL), dried over Na2SO4, filtered and concentrated to
obtain 10c as a white solid (219mg, 98%).
1H NMR (300MHz, CDCl3): δ 8.08–7.98 (m, 2H), 7.88 (dd,
J=8.7 Hz, 2.4 Hz, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.34 (d, J=7.8 Hz,
1H), 7.05 (d, J=8.7 Hz, 1H), 5.83–5.62 (m, 2H), 4.86–4.75 (m, 1H),
3.83 (s, 3H), 3.35–3.24 (m, 1H), 3.08–2.95 (m, 1H), 2.75 (t, J=6.3 Hz,
1H), 2.23 (s, 3H), 2.19–1.42 (m, 15H).
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4.6.2.4. cis-2-Cycloheptyl-4-(4-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
(11). To an argon-purged solution of 9 (1.7 g, 3.8 mmol) in 1,4-dioxane
(30mL) was added KOAc (0.75 g, 7.7 mmol), bis(pinacolato)diboron
(1.1 g, 4.2mmol) and PdCl2(dppf) (0.14 g, 0.19mmol). The mixture
was heated to reflux for 2.5 h. The reaction mixture was diluted with
DCM (150mL) and the mixture was washed with water (2×100mL)
and brine (100mL). The organic phase was dried over Na2SO4, filtered
and concentrated. The residue was purified on a silica gel column
eluting with EtOAc/n-heptane (gradient, 10–30%) to afford 11 as a
white solid (0.5 g, 28%).
1H-NMR (400MHz, CDCl3): δ 8.01–7.95 (m, 2H), 6.92 (d,
J= 8.7 Hz, 1H), 5.83–5.63 (m, 2H), 4.89–4.75 (m, 1H), 3.88 (s, 3H),
3.35 (q, J= 5.8 Hz, 1H), 3.03 (app d, 1H), 2.70 (t, J= 5.7 Hz, 1H),
2.23–1.21 (m, 24H).
LC-MS (ESI): tR=2.54min, area:> 95%, m/z 479 [M+H]+.
4.6.2.5. N-(2-Amino-2-oxoethyl)-4-bromo-3-fluorobenzamide (12a). To
a solution of 4-bromo-3-fluorobenzoic acid (500mg, 2.28mmol) in
DCM (25mL) was added DIPEA (0.63mL, 3.65mmol), glycinamide.HCl
(252mg, 2.28mmol), EDC.HCl (481mg, 2.51mmol) and HOAt (31mg,
0.23mmol). The reaction mixture was stirred overnight at rt and
poured into water (120mL). The solids were isolated by vacuum
filtration to obtain 12a as a white solid (338mg, 58%).
1H NMR (300MHz, DMSO-d6): δ 8.87 (t, J=6.0 Hz, 1H), 7.88–7.81
(m, 2H), 7.68 (dd, J=8.4 Hz, 2.1 Hz, 1H), 7.41 (br, 1H), 7.06 (br, 1H),
3.82 (d, J=6.0 Hz, 2H).
4.6.2.6. N-(2-Amino-2-oxoethyl)-4-bromo-3-methoxybenzamide
(12b). This compound was prepared from 4-bromo-3-methoxybenzoic
acid (500mg, 2.16mmol) and glycinamide.HCl (300mg, 2.74mmol) as
described for 12a. The title compound was obtained as a white solid
(385mg, 59% yield).
1H NMR (300MHz, DMSO-d6): δ 8.78 (t, J=5.7 Hz, 1H), 7.70 (d,
J=8.1 Hz, 1H), 7.57 (d, J=1.8 Hz, 1H), 7.46–7.35 (m, 2H), 7.05 (br,
1H), 3.92 (s, 3H), 3.81 (d, J=6.0 Hz, 2H).
4.6.2.7. N-(2-Amino-2-oxoethyl)-4-bromo-2-methylbenzamide
(12c). This compound was prepared from 4-bromo-2-methylbenzoic
acid (500mg, 2.33mmol) and glycinamide.HCl (514mg, 4.65mmol) as
described for 12a. The title compound was obtained as a light-brown
solid (300mg, 47%).
1H NMR (300MHz, DMSO-d6): δ 8.46–8.36 (m, 1H), 7.52–7.29 (m,
4H), 7.02 (br, 1H), 3.78 (d, J=6.0 Hz, 2H), 2.35 (br, 3H).
4.6.2.8. N-(2-Amino-2-oxoethyl)-4-bromo-2-methoxybenzamide
(12d). This compound was prepared from 4-bromo-2-methoxybenzoic
acid (500mg, 2.16mmol) and glycinamide.HCl (478mg, 4.33mmol) as
described for 12a. The title compound was obtained as a white solid
(350mg, 55%).
1H NMR (300MHz, DMSO-d6): δ 8.52–8.42 (m, 1H), 7.80 (d,
J=8.1 Hz, 1H), 7.43–7.34 (m, 2H), 7.27 (dd, J=8.1 Hz, 1.8 Hz, 1H),
7.10 (br, 1H), 3.95 (s, 3H), 3.88 (d, J=6.0 Hz, 2H).
4.6.2.9. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-fluoro-2′-methoxy-[1,1′-
biphenyl]-4-carboxamide (4a). To an argon purged solution of 11
(0.20 g, 0.42mmol) and 12a (0.12 g, 0.42mmol) in DME (3.2 mL)
was added an aqueous solution of Na2CO3 (1.6M, 0.40mL) and
PdCl2(dppf) (19mg, 0.02mmol). The reaction mixture was stirred at
100 °C for 1 h. The reaction mixture was diluted with water (8mL) and
washed with EtOAc (25mL). The water phase was acidified to ∼pH 5
with HCl (aq. 2M) and extracted with EtOAc (4×20mL). The
combined organic phases were washed with water (3×20mL), brine
(20mL), dried over Na2SO4 and concentrated. The residue was purified
on a reverse phase silica gel column eluting with MeCN/H2O+0.1%
formic acid (gradient, 5–95%) to afford 4a as a light yellow solid
(62mg, 27%).
1H NMR (500MHz, DMSO-d6): δ 8.84 (t, J=6.0 Hz, 1H), 7.93 (dd,
J=8.7, 2.2 Hz, 1H), 7.81–7.71 (m, 3H), 7.51 (t, J=7.6 Hz, 1H), 7.43
(s, 1H), 7.23 (d, J=8.8 Hz, 1H), 7.09 (s, 1H), 5.72–5.58 (m, 2H), 4.67
(tt, J=8.8, 4.8 Hz, 1H), 3.83 (d, J=5.9 Hz, 2H), 3.80 (s, 3H), 3.47 (dt,
J=11.6, 5.8 Hz, 1H), 2.79 (t, J=6.2 Hz, 1H), 2.76–2.68 (m, 1H),
2.19–2.08 (m, 2H), 1.95–1.64 (m, 7H), 1.59–1.39 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 171.3, 166.0, 165.4, 160.5, 158.6,
158.1, 153.8, 136.0, 132.3, 128.9, 128.6, 128.3, 127.8, 126.3, 124.5,
124.3, 123.7, 114.9, 112.1, 56.4, 55.5, 42.9, 34.2, 33.3, 33.0, 30.3,
28.5, 28.5, 25.0, 24.9, 23.0, 22.4.
LC-MS (ESI): tR=4.75min, area: 97%, m/z 547 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C31H36N4O4F 547.2715, found
547.2702.
4.6.2.10. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-2-methyl-[1,1′-
biphenyl]-4-carboxamide (4b). To a solution of glycinamide.HCl
(34.1 mg, 0.31mmol) and 10c (75mg, 0.15mmol) in DCM (3mL)
was added DIPEA (0.34mmol, 60 µL), EDC.HCl (65mg, 0.34mmol) and
HOAt (42mg, 0.31mmol). The mixture was stirred at rt for 1 h. The
reaction mixture was diluted with water (10mL) and extracted with
EtOAc (3×25mL). The combined organic phases were washed with
water (15mL), brine (15mL), dried over Na2SO4, filtered and
concentrated. The residue was purified on a reverse phase silica gel
column eluting with MeCN/H2O+0.1% formic acid (gradient, 5–95%)
to afford 4b as a light yellow solid (71mg, 83%).
1H NMR (500MHz, DMSO-d6): δ 8.69 (t, J=5.9 Hz, 1H), 7.90 (dd,
J=8.8, 2.2 Hz, 1H), 7.81 (s, 1H), 7.74 (dd, J=7.8, 1.7 Hz, 1H), 7.60
(d, J=2.1 Hz, 1H), 7.41 (s, 1H), 7.25 (d, J=7.8 Hz, 1H), 7.21 (d,
J=8.7 Hz, 1H), 7.09 (s, 1H), 5.73–5.58 (m, 2H), 4.68 (tt, J=9.6,
5.0 Hz, 1H), 3.83 (d, J=5.8 Hz, 2H), 3.78 (s, 3H), 3.46 (dt, J=11.6,
5.7 Hz, 1H), 2.80 (t, J=6.1 Hz, 1H), 2.77–2.68 (m, 1H), 2.13 (s, 5H),
1.93–1.65 (m, 7H), 1.61–1.40 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 171.5, 166.8, 166.0, 157.8, 154.0,
141.4, 136.7, 133.7, 130.3, 130.0, 129.0, 128.1, 127.6, 127.6, 126.4,
125.1, 124.5, 111.9, 56.1, 55.5, 42.9, 34.2, 33.3, 33.1, 30.3, 28.5, 28.5,
25.0, 24.9, 23.0, 22.4, 20.1.
LC-MS (ESI): tR=4.80min, area:> 98%, m/z 543 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C32H39N4O4 543.2966, found
543.2949.
4.6.2.11. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2,2′-dimethoxy-[1,1′-biphenyl]-
4-carboxamide (4c). This compound was prepared from 11 (100mg,
0.21mmol) and 12b (60mg, 0.21mmol) as described for 4a. The title
compound was obtained as a light yellow solid (62mg, 52%).
1H NMR (500MHz, DMSO-d6): δ 8.75 (t, J=6.0 Hz, 1H), 7.83 (dd,
J=8.7, 2.1 Hz, 1H), 7.64 (d, J=2.3 Hz, 1H), 7.56 (s, 1H), 7.52 (d,
J=7.8 Hz, 1H), 7.40 (s, 1H), 7.27 (d, J=7.7 Hz, 1H), 7.15 (d,
J=8.7 Hz, 1H), 7.08 (s, 1H), 5.72–5.58 (m, 2H), 4.71–4.62 (m, 1H),
3.84 (d, J=5.8 Hz, 2H), 3.77 (s, 3H), 3.75 (s, 3H), 3.43 (dt, J=11.7,
5.8 Hz, 1H), 2.81–2.68 (m, 2H), 2.20–2.07 (m, 2H), 1.94–1.64 (m, 7H),
1.61–1.37 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 171.5, 166.6, 166.0, 158.4, 157.0,
154.0, 135.2, 131.3, 130.4, 128.6, 127.4, 127.4, 127.3, 126.4, 124.5,
119.8, 111.9, 110.6, 56.2, 56.1, 55.4, 42.9, 34.2, 33.3, 33.0, 30.4, 28.6,
28.5, 24.9, 24.9, 23.1, 22.4.
LC-MS (ESI): tR=4.65min, area: 95%, m/z 559 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C32H39N4O5 559.2915, found
559.2913.
4.6.2.12. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-3-fluoro-2′-methoxy-[1,1′-
biphenyl]-4-carboxamide (4d). This compound was prepared from 10a
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(150mg, 0.31mmol) and glycinamide.HCl (68mg, 0.61mmol) as
described for 4b. The title compound was obtained as a light yellow
solid (40mg, 23%).
1H NMR (500MHz, DMSO-d6): δ 8.43–8.34 (m, 1H), 7.92 (dd,
J=8.8, 2.3 Hz, 1H), 7.84–7.76 (m, 2H), 7.51–7.40 (m, 3H), 7.26 (d,
J=8.8 Hz, 1H), 7.19–7.12 (m, 1H), 5.75–5.58 (m, 2H), 4.69 (tt,
J=9.0, 4.4 Hz, 1H), 3.86 (d, J=8.3 Hz, 5H), 3.53 (dt, J=11.6,
5.7 Hz, 1H), 2.82–2.69 (m, 2H), 2.21–2.09 (m, 2H), 1.97–1.88 (m, 1H),
1.87–1.67 (m, 6H), 1.62–1.41 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 170.9, 166.0, 163.7, 160.6, 158.6,
157.7, 153.9, 142.8, 130.7, 128.3, 128.1, 126.3, 125.8, 124.5, 121.8,
117.4, 112.7, 56.4, 55.4, 42.9, 34.2, 33.3, 33.1, 30.2, 28.7, 28.6, 25.0,
24.9, 23.0, 22.4.
LC-MS (ESI): tR=4.87min, area:> 98%, m/z 547 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C31H36N4O4F 547.2707, found
547.2715.
4.6.2.13. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′-methoxy-3-methyl-[1,1′-
biphenyl]-4-carboxamide (4e). This compound was prepared from 11
(200mg, 0.42mmol) and 12c (113mg, 0.42mmol) as described for 4a.
The title compound was obtained as a light yellow solid (130mg, 57%).
1H NMR (500MHz, DMSO-d6): δ 8.39 (t, J=6.0 Hz, 1H), 7.85 (dd,
J=8.7, 2.2 Hz, 1H), 7.74 (d, J=2.1 Hz, 1H), 7.48 (d, J=7.8 Hz, 1H),
7.40–7.30 (m, 3H), 7.20 (d, J=8.7 Hz, 1H), 7.06 (s, 1H), 5.73–5.57
(m, 2H), 4.73–4.64 (m, 1H), 3.85–3.75 (m, 5H), 3.52–3.43 (m, 1H),
2.82–2.69 (m, 2H), 2.40 (s, 3H), 2.20–2.07 (m, 2H), 1.95–1.65 (m, 7H),
1.62–1.38 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 171.3, 169.6, 166.0, 157.8, 154.0,
139.3, 135.9, 135.7, 131.7, 130.0, 128.1, 127.8, 127.6, 127.4, 126.8,
126.4, 124.5, 112.3, 56.3, 55.3, 42.6, 34.2, 33.3, 33.0, 30.3, 28.7, 28.7,
24.9, 24.8, 23.0, 22.4, 20.1.
LC-MS (ESI): tR=4.83min, area: 98%, m/z 543 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C32H39N4O4 543.2950, found
543.2966.
4.6.2.14. N-(2-Amino-2-oxoethyl)-5′-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2′,3-dimethoxy-[1,1′-biphenyl]-
4-carboxamide (4f). This compound was prepared from 11 (200mg,
0.42mmol) and 12d (120mg, 0.42mmol) as described for 4a. The title
compound was obtained as a light yellow solid (137mg, 58%).
1H NMR (500MHz, DMSO-d6): δ 8.57 (t, J=5.3 Hz, 1H), 7.93 (d,
J=8.0 Hz, 1H), 7.89 (dd, J=8.7, 2.2 Hz, 1H), 7.83 (d, J=2.1 Hz,
1H), 7.42 (s, 1H), 7.28–7.18 (m, 3H), 7.14 (s, 1H), 5.74–5.59 (m, 2H),
4.70 (tt, J=8.5, 4.9 Hz, 1H), 3.97 (s, 3H), 3.92 (d, J=5.2 Hz, 2H),
3.85 (s, 3H), 3.50 (dt, J=11.5, 5.7 Hz, 1H), 2.83–2.71 (m, 2H),
2.22–2.09 (m, 2H), 1.97–1.68 (m, 7H), 1.62–1.41 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 171.1, 166.0, 164.7, 157.8, 157.4,
153.9, 142.7, 131.0, 129.6, 128.2, 127.9, 127.7, 126.4, 124.5, 122.2,
120.9, 113.6, 112.5, 56.5, 56.4, 55.4, 43.1, 34.3, 33.3, 33.1, 30.3, 28.8,
28.7, 24.9, 24.8, 23.0, 22.4.
LC-MS (ESI): tR=4.86min, area: 97%, m/z 559 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C32H39N4O5 559.2915, found
559.2887.
4.6.2.15. cis-2-Cycloheptyl-4-(4-methoxy-3-(1-oxoisoindolin-5-yl)phenyl)-
4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (5a). To an argon purged
solution of 9 (1.4 g, 3.1mmol) in DME (15mL) was added 5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (0.84 g, 3.2mmol),
PdCl2(dppf) (0.11 g, 0.15mmol) and aq. Na2CO3 (2M, 9.3mmol,
4.6mL). The reaction mixture was stirred at 100 °C for 5 h. The reaction
mixture was diluted with DCM (250mL) and washed with sat. aq. NH4Cl
(150mL), water (150mL) and brine (200mL). The organic phase was
dried over Na2SO4, filtered and concentrated. The residue was purified on
a reverse phase silica gel column eluting with MeCN/H2O+0.1% formic
acid (gradient, 5–95%) to afford 5a as a light brown solid (1.2 g, 73%).
1H NMR (500MHz, DMSO-d6): δ 8.61 (s, 1H), 7.92 (dd, J=8.7,
2.2 Hz, 1H), 7.76 (d, J=2.2 Hz, 1H), 7.72 (d, J=7.9 Hz, 1H), 7.68 (s,
1H), 7.59 (d, J=7.8 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 5.75–5.59 (m,
2H), 4.69 (tt, J=10.0, 4.7 Hz, 1H), 4.43 (s, 2H), 3.83 (s, 3H), 3.50 (dt,
J=11.5, 5.7 Hz, 1H), 3.34 (s, 1H), 2.80 (t, J=6.1 Hz, 1H), 2.77–2.69
(m, 1H), 2.21–2.09 (m, 2H), 1.96–1.67 (m, 6H), 1.62–1.40 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 170.2, 166.0, 157.7, 154.0, 144.5,
141.4, 131.9, 129.9, 129.5, 128.5, 128.0, 127.6, 126.4, 125.0, 124.5,
122.8, 112.6, 56.4, 55.4, 45.4, 34.2, 33.3, 33.1, 30.3, 28.6, 28.6, 25.0,
24.9, 23.0, 22.4.
LC-MS (ESI): tR=5.05min, area:> 98%, m/z 484 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C30H34N3O3 484.2595, found
484.2585.
4.6.2.16. cis-2-Cycloheptyl-4-(4-methoxy-3-(2-(2-methoxyethyl)-1-
oxoisoindolin-5-yl)phenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
(5b). To an ice-cooled solution of 5a (0.10 g, 0.19mmol) in DMF
(1.5mL) was added NaH (23mg, 0.57mmol, 60%). The mixture was
stirred for 0.5 h at rt prior to the addition of 1-bromo-2-methoxyethane
(40 µL, 0.41mmol). The reaction mixture was stirred at rt for 1.5 h. The
reaction mixture was quenched with water (20mL) and extracted with
DCM (2× 30mL). The combined organic phases were washed with
brine (25mL), dried over Na2SO4, filtered and concentrated. The
residue was purified on a silica gel column eluting with EtOAc/n-
heptane (gradient, 25–66%) to afford 5b as a white solid (31mg, 27%).
1H NMR (500MHz, DMSO-d6): δ 7.91 (dt, J=8.8, 1.8 Hz, 1H), 7.76
(t, J=1.9 Hz, 1H), 7.75–7.68 (m, 2H), 7.60 (d, J=7.8 Hz, 1H), 7.25
(dd, J=8.8, 1.2 Hz, 1H), 5.74–5.59 (m, 2H), 4.73–4.65 (m, 1H), 4.57
(s, 2H), 3.84 (d, J=1.3 Hz, 3H), 3.72 (t, J=5.4 Hz, 2H), 3.59 (t,
J=5.4 Hz, 2H), 3.50 (dt, J=11.6, 5.8 Hz, 1H), 3.29 (s, 3H), 2.83–2.71
(m, 2H), 2.22–2.09 (m, 2H), 1.97–1.67 (m, 7H), 1.61–1.42 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 167.5, 166.0, 157.7, 154.0, 142.4,
141.3, 131.6, 129.9, 129.6, 128.5, 128.0, 127.6, 126.4, 124.7, 124.5,
122.7, 112.6, 70.6, 58.4, 56.4, 55.5, 50.8, 41.8, 34.3, 33.3, 33.1, 30.4,
28.6, 28.6, 25.0, 24.9, 23.0, 22.4.
LC-MS (ESI): tR=5.39min, area: 95%, m/z 542 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C33H40N3O4 542.3013, found
542.3000.
4.6.2.17. 2-(5-(5-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)-1-oxoisoindolin-2-yl)
acetamide (5c). This compound was prepared from 5a (0.10mg,
0.21mmol) and 2-bromoacetamide (31mg, 0.23mmol) as described
for 5b. The title compound was obtained as a white solid (29mg, 26%).
1H NMR (500MHz, DMSO-d6): δ 7.91 (dd, J=8.7, 2.2 Hz, 1H),
7.78 (d, J=2.3 Hz, 1H), 7.75 (d, J=7.9 Hz, 1H), 7.71 (s, 1H), 7.61 (d,
J=7.8 Hz, 1H), 7.57 (s, 1H), 7.26 (d, J=8.7 Hz, 1H), 7.17 (s, 1H),
5.74–5.59 (m, 2H), 4.69 (tt, J=8.8, 4.9 Hz, 1H), 4.57 (s, 2H), 4.16 (s,
2H), 3.84 (s, 3H), 3.50 (dt, J=11.5, 5.7 Hz, 1H), 2.83–2.70 (m, 2H),
2.22–2.10 (m, 2H), 1.97–1.67 (m, 7H), 1.61–1.41 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 170.4, 168.0, 166.0, 157.8, 154.0,
142.7, 141.5, 131.3, 130.0, 129.6, 128.5, 128.0, 127.7, 126.4, 124.7,
124.5, 122.9, 112.6, 56.4, 55.5, 51.0, 45.0, 34.3, 33.3, 33.1, 30.4, 28.6,
28.6, 25.0, 24.9, 23.0, 22.4.
LC-MS (ESI): tR=4.75min, area:> 98%, m/z 541 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C32H37N4O4 541.2809, found
541.2788.
4.6.2.18. N-(2-Amino-2-oxoethyl)-3-(5-(cis-3-cycloheptyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide
(8g). A N2-flushed mixture of 9 (1.0 g, 2.32mmol), Pd(PPh3)2Cl2
(49.0 mg, 0.07mmol), propiolic acid (0.16mL, 2.55mmol), DBU
(1.73mL, 11.59mmol) and dppb (79.0 mg, 0.19mmol) in DMSO
(6mL) was stirred at 50 °C for 15 h. The reaction mixture was diluted
with EtOAc (300mL) and washed with sat. aq. NaHCO3 (150mL). The
aqueous phase was acidified using sat. aq. NH4Cl (∼250mL) and
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extracted with EtOAc (2×400mL). The combined organic phases were
dried over Na2SO4, filtered and concentrated to obtain the crude
material of carboxylic acid 13 (320mg). A portion of the residue
(100mg) was dissolved in DMF (3mL) and glycinamide.HCl (52mg,
0.48mmol), DIPEA (0.10mL, 0.60mmol), EDC (50mg, 0.26mmol) and
HOAt (32mg, 0.24mmol) were added. This mixture was stirred at rt for
30 h. The reaction mixture was diluted with water (25mL) and
extracted with EtOAc (3× 75mL). The combined organic phases
were combined and washed with water (4× 25mL) and brine
(3× 25mL). The organic phase was dried over Na2SO4 and
concentrated. The residue was purified on a silica gel column eluting
with MeOH/DCM (gradient, 0–1.5%) to afford 8g as a white solid
(6mg). The extrapolated yield of this reaction is 1.5%.
1H NMR (500MHz, DMSO-d6): δ 8.91 (t, J=6.1 Hz, 1H), 7.98 (dd,
J=8.9, 2.3 Hz, 1H), 7.95 (d, J=2.3 Hz, 1H), 7.43 (s, 1H), 7.23 (d,
J=8.9 Hz, 1H), 7.09 (s, 1H), 5.74–5.58 (m, 2H), 4.67 (tt, J=9.0,
4.4 Hz, 1H), 3.92 (s, 3H), 3.72 (d, J=6.0 Hz, 2H), 3.45 (dt, J=11.7,
5.8 Hz, 1H), 2.81 (t, J=6.1 Hz, 1H), 2.74 (app. d, 1H), 2.14 (app. t,
2H), 1.98–1.89 (m, 1H), 1.83–1.67 (m, 6H), 1.61–1.43 (m, 7H).
13C NMR (126MHz, DMSO-d6): δ 170.5, 166.1, 161.8, 153.1, 153.1,
131.6, 130.0, 127.9, 126.4, 124.4, 112.4, 109.5, 88.2, 80.7, 56.6, 55.7,
42.3, 34.1, 33.3, 33.1, 30.3, 28.4, 28.3, 25.0, 24.9, 22.9, 22.4.
LC-MS (ESI): tR=4.44min, area:> 98%, m/z 477 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C27H33N4O4 477.2496, found
477.2480.
4.6.2.19. Methyl-3-(5-(cis-3-cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolate (14). To a
solution of 11 (900mg, 1.88mmol) in anhydrous acetonitrile (15mL)
was added Pd(II)(OAc)2 (21mg, 94 µmol), K2CO3 (520mg, 3.76mmol),
Ag(II)O (654mg, 2.82mmol) and methyl propiolate (174mg,
2.07mmol, 0.18mL). The mixture was heated to 70 °C for 2.5 h. The
reaction mixture was filtered over Hyflo. The filtrate was diluted with
EtOAc (15mL) and washed with water (2×10mL) and brine (10mL).
The organic phase was dried over Na2SO4, filtered and concentrated.
The residue was purified on a silica gel column eluting with EtOAc/n-
heptane (gradient, 10–20%) to afford 14 as a white solid (489mg,
53%).
1H-NMR (300MHz, DMSO-d6): δ 8.05 (dd, J=2.3 Hz, J=8.8 Hz,
1H), 8.01 (d, J=2.3 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 5.81–5.53 (m,
2H), 4.13–4.01 (m, 1H), 3.93 (s, 3H), 3.78 (s, 3H), 3.48 (q, J=5.6 Hz,
1H), 2.82–2.68 (m, 2H), 2.21–2.05 (m, 2H), 1.98–1.36 (m, 13H).
LC-MS (ESI): tR=3.95min, area:> 95%, m/z 435 [M+H]+.
4.6.2.20. 3-(5-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide
(8b). Compound 14 (60mg, 0.12mmol) was dissolved in a solution of
NH3 in MeOH (7M, 2mL). This mixture was stirred at rt for 2 h. The
solvent was evaporated to obtain 8b as a white solid (52mg, 89%).
1H NMR (500MHz, CDCl3): δ 7.99–7.84 (m, 2H), 7.02–6.90 (m,
1H), 6.35 (s, 1H), 6.14 (s, 1H), 5.85–5.59 (m, 2H), 4.88–4.72 (m, 1H),
3.94 (s, 3H), 3.25 (dt, J=11.5, 5.7 Hz, 1H), 3.05–2.92 (m, 1H), 2.72 (t,
J=6.0 Hz, 1H), 2.26–2.08 (m, 2H), 2.05–1.95 (m, 2H), 1.92–1.84 (m,
1H), 1.82–1.69 (m, 4H), 1.69–1.43 (m, 6H), 1.34–1.20 (m, 2H).
13C NMR (126MHz, CDCl3): δ 165.9, 161.9, 155.2, 152.3, 132.0,
129.5, 127.9, 126.0, 123.8, 111.0, 109.5, 86.5, 82.3, 56.4, 56.1, 34.6,
33.2, 33.0, 30.9, 28.2, 28.1, 25.1, 25.0, 22.9, 22.3.
LC-MS (ESI): tR=4.82min, area:> 98%, m/z 420 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C25H30N3O3 420.2282, found
420.2278.
4.6.2.21. N-Butyl-3-(5-(cis-3-cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide (8c). To an
ice-cooled solution of 14 (60mg, 0.12mmol) and butan-1-amine
(15 µL, 0.15mmol) in toluene (2mL) was slowly added AlMe3 in
toluene (2M, 93 µL, 0.19mmol,). The reaction mixture was stirred at
50 °C for 1 day. The reaction mixture was diluted with water (10mL)
and extracted with EtOAc (3×15mL). The combined organic phases
were washed with brine (25mL), dried over Na2SO4, filtered and
concentrated. The residue was purified on a silica gel column eluting
with MeOH/DCM (gradient, 0–1.5%) to afford 8c as a white solid
(10mg, 17%).
1H NMR (500MHz, DMSO-d6): δ 8.75 (t, J=5.8 Hz, 1H), 7.95 (dd,
J=8.9, 2.3 Hz, 1H), 7.90 (d, J=2.3 Hz, 1H), 7.21 (d, J=9.0 Hz, 1H),
5.73–5.57 (m, 2H), 4.65 (tt, J=9.7, 4.5 Hz, 1H), 3.90 (s, 3H),
3.47–3.39 (m, 1H), 3.16–3.07 (m, 2H), 2.78 (t, J=6.1 Hz, 1H),
2.76–2.67 (m, 1H), 2.20–2.03 (m, 2H), 1.96–1.85 (m, 1H), 1.85–1.18
(m, 16H), 0.87 (t, J=7.3 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.0, 161.7, 153.1, 152.6, 131.5,
129.8, 127.8, 126.3, 124.4, 112.4, 109.6, 88.4, 79.9, 56.5, 55.6, 39.1,
34.1, 33.3, 33.1, 31.3, 30.3, 28.4, 28.3, 25.0, 24.9, 22.8, 22.4, 20.0,
14.1.
LC-MS (ESI): tR=5.56min, area:> 98%, m/z 476 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C29H38N3O3 476.2908, found
476.2887.
4.6.2.22. 3-(5-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)-N-(2-methoxyethyl)
propiolamide (8d). This compound was prepared from 14 (60mg,
0.12mmol) and 2-methoxyethanamine (13 µL, 0.15mmol) as
described for 8c. The title compound was obtained as a white solid
(11mg, 19%).
1H NMR (500MHz, DMSO-d6): δ 8.83 (t, J=5.7 Hz, 1H), 8.02–7.89
(m, 2H), 7.21 (d, J=8.9 Hz, 1H), 5.75–5.56 (m, 2H), 4.66 (tt, J=9.5,
4.8 Hz, 1H), 3.90 (s, 3H), 3.47–3.37 (m, 3H), 3.33–3.26 (m, 2H), 3.25
(s, 3H), 2.84–2.67 (m, 2H), 2.19–2.05 (m, 2H), 1.97–1.86 (m, 1H),
1.84–1.37 (m, 13H).
13C NMR (126MHz, DMSO-d6): δ 166.0, 161.8, 153.1, 152.9, 131.5,
129.9, 127.8, 126.3, 124.4, 112.4, 109.6, 88.3, 80.2, 70.5, 58.3, 56.6,
55.6, 39.2, 34.1, 33.3, 33.1, 30.3, 28.4, 28.3, 25.0, 24.9, 22.8, 22.4.
LC-MS (ESI): tR=5.12min, area:> 98%, m/z 478 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C28H36N3O4 478.2700, found
478.2678.
4.6.2.23. cis-2-Cycloheptyl-4-(4-methoxy-3-(3-morpholino-3-oxoprop-1-
yn-1-yl)phenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (8e). This
compound was prepared from 14 (60mg, 0.12mmol) and morpholine
(11 µL, 0.12mmol) as described for 8c. The title compound was
obtained as a white solid (22mg, 37%).
1H NMR (500MHz, DMSO-d6): δ 8.03–7.96 (m, 2H), 7.24 (d,
J=8.7 Hz, 1H), 5.74–5.57 (m, 2H), 4.65 (m, J=9.3, 4.3 Hz, 1H), 3.92
(s, 3H), 3.83 (t, J=4.8 Hz, 2H), 3.69 (t, J=4.8 Hz, 2H), 3.64–3.53 (m,
4H), 3.48 (dt, J=11.6, 5.8 Hz, 1H), 2.79 (t, J=6.1 Hz, 1H), 2.77–2.69
(m, 1H), 2.21–2.05 (m, 2H), 1.98–1.87 (m, 1H), 1.85–1.65 (m, 6H),
1.63–1.39 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 166.1, 162.1, 153.1, 152.4, 131.5,
130.4, 128.0, 126.3, 124.5, 112.4, 109.2, 86.7, 85.7, 66.7, 66.2, 56.8,
55.5, 47.2, 42.0, 34.2, 33.3, 33.1, 30.1, 28.5, 28.5, 25.0, 24.9, 22.8,
22.4.
LC-MS (ESI): tR=5.23min, area:> 98%, m/z 490 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C29H36N3O4 490.2700, found
490.2684.
4.6.2.24. 3-(5-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)-N-(furan-2-ylmethyl)
propiolamide (8f). This compound was prepared from 14 (60mg,
0.12mmol) and furan-2-ylmethanamine (13 µL, 0.15mmol) as
described for 8c. The title compound was obtained as a white solid
(10mg, 16%).
1H NMR (500MHz, CDCl3): δ 8.01–7.83 (m, 2H), 7.39 (s, 1H), 6.95
(d, J=8.6 Hz, 1H), 6.42 (t, J=5.7 Hz, 1H), 6.38–6.28 (m, 2H),
5.84–5.62 (m, 2H), 4.85–4.74 (m, 1H), 4.55 (d, J=5.6 Hz, 2H), 3.93
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(s, 3H), 3.24 (dt, J=11.5, 5.7 Hz, 1H), 3.07–2.94 (m, 1H), 2.71 (t,
J=6.1 Hz, 1H), 2.27–2.09 (m, 2H), 2.05–1.93 (m, 2H), 1.93–1.83 (m,
1H), 1.83–1.69 (m, 4H), 1.69–1.43 (m, 6H),
13C NMR (126MHz, CDCl3): δ 165.9, 161.8, 153.1, 152.3, 150.3,
142.4, 132.0, 129.3, 127.9, 126.0, 123.7, 111.0, 110.6, 109.6, 108.1,
86.8, 81.6, 56.4, 56.1, 36.7, 34.6, 33.2, 33.0, 30.9, 28.2, 28.1, 25.1,
25.0, 22.9, 22.3.
LC-MS (ESI): tR=5.35min, area:> 98%, m/z 500 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C30H34N3O4 500.2544, found
500.2539.
4.6.2.25. cis-2-Cycloheptyl-4-(4-methoxy-3-((trimethylsilyl)ethynyl)
phenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (15). To an argon
purged solution of Pd(PPh3)2Cl2 (15mg, 21mmol) and 9 (0.10 g,
0.21mmol) in Et3N (2.0 mL, 14mmol) was added
ethynyltrimethylsilane (60 µL, 0.43mmol) and CuI (4.0mg,
0.02mmol). The reaction mixture was stirred at 80 °C for 3 h. The
reaction mixture was filtered over Celite and partitioned between
EtOAc (40mL) and sat. aq. NH4Cl/H2O (1:2, 30mL). The organic
phase was washed with water (30mL) and brine (30mL), dried over
Na2SO4, filtered and concentrated. The residue was purified on a silica
gel column eluting with EtOAc/n-heptane (gradient, 5–25%) to afford
15 as a white solid (77mg, 80%).
1H NMR (400MHz, DMSO-d6): δ 7.87 (dd, J=8.8, 1.8 Hz, 1H),
7.79 (d, J= 1.8 Hz, 1H), 7.15 (d, J=8.9 Hz, 1H), 5.76–5.56 (m, 2H),
4.77–4.57 (m, 1H), 3.86 (s, 3H), 3.48–3.40 (m, 1H), 2.84–2.63 (m, 2H),
2.27–1.13 (m, 15H), 0.23 (s, 9H).
LC-MS (ESI): tR=2.74min, area:> 97%, m/z 449 [M+H]+.
4.6.2.26. cis-2-Cycloheptyl-4-(3-ethynyl-4-methoxyphenyl)-4a,5,8,8a-
tetrahydrophthalazin-1(2H)-one (8a). To a suspension of 15 (1.2 g,
3.04mmol) in MeOH (15mL) was added NaOH (1.0M, 6mL). The
mixture was stirred at rt for 2 h. The reaction mixture was diluted with
EtOAc (100mL) and washed with water (2×50mL) and brine (50mL).
The organic phase was dried over MgSO4, filtered and concentrated to
obtain 8a (890mg, 91%) as a light yellow solid.
1H NMR (500MHz, DMSO-d6): δ 7.91–7.85 (m, 2H), 7.19–7.12 (m,
1H), 5.74–5.59 (m, 2H), 4.68 (tt, J=9.2, 4.6 Hz, 1H), 4.31 (s, 1H),
3.88 (s, 3H), 3.44 (dt, J=11.5, 5.7 Hz, 1H), 2.82–2.70 (m, 2H),
2.22–2.05 (m, 2H), 1.97–1.87 (m, 1H), 1.85–1.66 (m, 6H), 1.63–1.41
(m, 6H).
13C NMR (126MHz, DMSO-d6): δ 166.0, 161.6, 153.3, 131.2, 128.7,
127.7, 126.3, 124.4, 112.0, 111.5, 85.4, 80.2, 56.4, 55.6, 34.2, 33.3,
33.1, 30.3, 28.5, 28.5, 25.0, 24.9, 22.9, 22.4.
LC-MS (ESI): tR=5.60min, area: 95%, m/z 377 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C24H29N2O2 377.2224, found
377.2213.
4.6.2.27. 3-(5-(cis-3-Cycloheptyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolaldehyde
(16). Compound 8a (100mg, 0.266mmol) was dissolved in THF
(2mL) and the mixture was cooled to −78 °C. To this mixture was
added 1.6M n-BuLi in hexane (0.20mL, 0.32mmol,) and the mixture
was stirred for 30min prior to the addition of DMF (0.031mL,
0.40mmol). After 1.5 h, the reaction mixture was poured into
acidified ice water (50mL) and was neutralized to pH 6–7. The
product was extracted with EtOAc (3× 50mL). The combined
organic phases were washed with brine (100mL), dried over Na2SO4,
filtered and concentrated. The product was purified with flash column
chromatography (5–40% EtOAc/Hept) and to give 16 as a white solid
(74mg, 69%).
1H NMR (300MHz, DMSO-d6): δ 9.45 (s, 1H), 8.07–8.03 (m, 2H),
7.27 (d, J=8.9 Hz, 1H), 5.71–5.60 (m, 2H), 4.65 (hept, J=4.5 Hz,
1H), 3.94 (s, 3H), 3.47 (dt, J=11.4, 5.8 Hz, 1H), 2.80–2.67 (m, 2H),
2.15–2.04 (m, 2H), 1.96–1.43 (m, 13H)
4.6.2.28. cis-2-Cycloheptyl-4-(4-methoxy-3-(oxazol-5-ylethynyl)phenyl)-
4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (8h). To a solution of 16
(74mg, 0.18mmol) in MeOH (3mL) was added 1-((isocyanomethyl)
sulfonyl)-4-methylbenzene (38mg, 0.19mmol) and K2CO3 (28mg,
0.20mmol). This mixture was heated to reflux for 1.5 h. The mixture
was diluted with EtOAc (25mL) and washed with sat. aq. NH4Cl
(25mL), water (25mL) and brine (25mL). The organic phase was dried
over Na2SO4, filtered and concentrated to gain a brown oil. The product
was purified with reverse phase column purification to obtain the
product as a white solid after lyophilisation (38mg, 47%).
1H NMR (500MHz, DMSO-d6): δ 8.54 (s, 1H), 7.96 (s, 2H), 7.67 (s,
1H), 7.24 (d, J=8.6 Hz, 1H), 5.75–5.58 (m, 2H), 4.68 (tt, J=9.3,
4.5 Hz, 1H), 3.93 (s, 3H), 3.48 (dt, J=11.5, 5.8 Hz, 1H), 2.80 (t,
J=6.0 Hz, 1H), 2.77–2.69 (m, 1H), 2.21–2.07 (m, 2H), 1.99–1.88 (m,
1H), 1.86–1.66 (m, 6H), 1.63–1.42 (m, 6H).
13C NMR (126MHz, DMSO-d6): δ 166.1, 161.2, 153.7, 153.2, 134.3,
131.4, 130.9, 129.7, 127.9, 126.3, 124.4, 112.4, 110.2, 94.2, 79.9,
56.7, 55.6, 34.2, 33.3, 33.1, 30.2, 28.4, 28.4, 25.0, 24.9, 22.8, 22.4.
LC-MS (ESI): tR=5.58min, area: 97%, m/z 444 [M+H] +.
HRMS (ESI) m/z: [M+H]+ calcd. for C27H30N3O3 444.2282, found
444.2266.
4.6.2.29. cis-5-(5-(3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)thiophene-2-carboxylic acid (18). To a solution of
17 (1.00 g, 2.65mmol) and 5-borono-thiophene-2-carboxylic acid
(0.830 g, 4.85mmol) in DME (10mL) was added aq. Na2CO3 (1M,
6.6 mL, 6.63mmol) and PdCl2(dppf) (97.0 mg, 0.133mmol). The
reaction mixture was heated to 120 °C in the microwave for 3 h and
then filtered over Celite using EtOAc (100mL). The filtrate was washed
with 1M aq. HCl (2×150mL), brine (10mL), dried over MgSO4,
filtered and concentrated in vacuo. The residue was purified on a silica
gel column eluting with EtOAc/n-heptane+ 5% AcOH (gradient,
5–35%) to afford 18 as a white solid (610mg, 49%).
1H NMR (500MHz, DMSO-d6): δ 8.21 (d, J=2.2 Hz, 1H), 7.89 (dd,
J=8.8, 2.2 Hz, 1H), 7.74 (d, J=4.0 Hz, 1H), 7.70 (d, J=4.0 Hz, 1H),
7.26 (d, J=8.8 Hz, 1H), 5.74–5.60 (m, 2H), 4.89 (hept, J=6.7 Hz,
1H), 3.99 (s, 3H), 3.58 (dt, J=11.6, 5.8 Hz, 1H), 2.81 (t, J=6.1 Hz,
1H), 2.79–2.72 (m, 1H), 2.23–2.10 (m, 2H), 1.86–1.77 (m, 1H), 1.25 (d,
J=6.5 Hz, 3H), 1.16 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.2, 163.4, 156.4, 153.4, 144.1,
134.6, 132.6, 127.8, 127.6, 126.4, 125.9, 125.3, 124.2, 121.6, 112.7,
56.2, 45.8, 34.0, 29.8, 22.6, 22.0, 20.6, 20.2.
LC-MS (ESI): tR=4.81min, area:> 98%, m/z 425 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C23H25N2O4S 425.1530, found
425.1541.
4.6.2.30. 5-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)thiophene-2-carboxamide (6a). To a solution of
18 (88.0 mg, 0.207mmol) in DCM (2mL) was added HOBt (73.0 mg,
0.540mmol) and EDC.HCl (100mg, 0.522mmol). This mixture was
stirred for 2 h at rt before NH3 in MeOH (7M, 0.5 mL, 3.50mmol) was
added. The reaction mixture was stirred for 22 h. EtOAc (2×10mL)
was added and the organic phase was washed with sat. aq. NH4Cl
(2×10mL) and brine (5mL), dried over MgSO4, filtered and
concentrated in vacuo. The residue was purified on a silica gel column
eluting with EtOAc/n-heptane (gradient, 35–100%) to afford 6a as a
white solid (58mg, 72%).
1H NMR (500MHz, CDCl3): δ 8.13 (d, J=2.2 Hz, 1H), 7.79 (dd,
J=8.7, 2.3 Hz, 1H), 7.55 (d, J=4.0 Hz, 1H), 7.51 (d, J=4.0 Hz, 1H),
7.04 (d, J=8.8 Hz, 1H), 6.04 (s, 2H), 5.83–5.76 (m, 1H), 5.72–5.65
(m, 1H), 5.05 (hept, J=6.6 Hz, 1H), 4.00 (s, 3H), 3.33 (dt, J=11.6,
5.8 Hz, 1H), 3.07–2.98 (m, 1H), 2.76 (t, J=6.0 Hz, 1H), 2.26–2.15 (m,
2H), 2.08–2.01 (m, 1H), 1.34 (d, J=6.6 Hz, 3H), 1.22 (d, J=6.7 Hz,
3H).
13C NMR (126MHz, CDCl3): δ 166.5, 164.3, 157.0, 153.2, 144.6,
136.9, 129.1, 128.2, 127.3, 126.2, 126.1, 126.1, 124.0, 122.6, 111.7,
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56.0, 46.9, 34.9, 31.2, 23.2, 22.5, 20.8, 20.4.
LC-MS (ESI): tR=4.47min, area: 97%, m/z 424 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C23H26N3O3S 424.1689, found
424.1683.
4.6.2.31. N-Butyl-5-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)thiophene-2-carboxamide
(6b). This compound was prepared from 18 (88.0mg, 0.207mmol)
and butan-1-amine (0.5 mL, 4.72mmol) as described for 6a. The title
compound was obtained as a white solid (77mg, 76%).
1H NMR (500MHz, CDCl3): δ 8.11 (d, J=2.3 Hz, 1H), 7.76 (dd,
J=8.7, 2.3 Hz, 1H), 7.51 (d, J=4.0 Hz, 1H), 7.47 (d, J=4.0 Hz, 1H),
7.02 (d, J=8.7 Hz, 1H), 6.29–6.17 (m, 1H), 5.85–5.73 (m, 1H),
5.73–5.62 (m, 1H), 5.04 (hept, J=6.8 Hz, 1H), 3.98 (s, 3H), 3.44 (q,
J=6.7 Hz, 2H), 3.33 (dt, J=11.6, 5.8 Hz, 1H), 3.07–2.96 (m, 1H),
2.75 (t, J=5.9 Hz, 1H), 2.27–2.13 (m, 2H), 2.08–1.99 (m, 1H), 1.60 (p,
J=7.4 Hz, 2H), 1.40 (h, J=7.4 Hz, 2H), 1.33 (d, J=6.6 Hz, 3H), 1.21
(d, J=6.7 Hz, 3H), 0.95 (t, J=7.4 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.5, 162.3, 156.9, 153.3, 143.1,
138.5, 128.1, 127.6, 127.0, 126.1, 126.1, 126.0, 124.0, 122.8, 111.7,
55.9, 46.8, 39.8, 34.8, 31.9, 31.1, 23.2, 22.4, 20.7, 20.3, 20.2, 13.9.
LC-MS (ESI): tR=5.30min, area:> 98%, m/z 480 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C27H34N3O3S 480.2315, found
480.2306.
4.6.2.32. 5-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)-N-(2-methoxyethyl)thiophene-2-carboxamide
(6c). This compound was prepared from 18 (212mg, 0.50mmol) and
2-methoxyethylamine (75mg, 1.0mmol) as described for 6a. The title
compound was obtained as a white solid (36mg, 15%).
1H NMR (250MHz, CDCl3): δ 8.12 (d, J=2.05 Hz, 1H), 7.77 (dd,
J=2.21, 8.69 Hz, 1H), 7.53–7.43 (m, 2H), 7.03 (d, J=8.69Hz, 1H),
6.43 (t, J=4.98 Hz, 1H), 5.86–5.60 (m, 2H), 5.15–4.95 (m, 1H), 3.99
(s, 3H), 3.72–3.50 (m, 4H), 3.40 (s, 3H), 3.37–3.26 (m, 1H), 3.10–2.92
(m, 1H), 2.76 (t, J=5.77 Hz, 1H), 2.32–2.07 (m, 3H), 1.34 (d,
J=6.63 Hz, 3H), 1.27–1.12 (m, 3H)
13C NMR (126MHz, CDCl3): δ 166.8, 162.6, 157.3, 153.5, 143.8,
138.4, 128.5, 128.2, 127.4, 126.3, 124.3, 123.0, 112.0, 77.7, 77.4,
71.6, 59.3, 56.2, 47.1, 40.0, 35.1, 31.5, 23.5, 22.7, 21.0, 20.6
LC-MS (ESI): tR=5.10min, area:> 98%, m/z 482 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C26H32N3O4 482.2108, found
482.2091.
4.6.2.33. N-(Furan-2-ylmethyl)-5-(5-(cis-3-isopropyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)thiophene-2-
carboxamide (6d). This compound was prepared from 18 (117mg,
0.276mmol) and furan-2-ylmethanamine (0.06mL, 0.63mmol) as
described for 6a. The title compound was obtained as a white solid
(82mg, 57%).
1H NMR (500MHz, CDCl3): δ 8.12 (d, J=2.3 Hz, 1H), 7.78 (dd,
J=8.7, 2.3 Hz, 1H), 7.52 (d, J=4.0 Hz, 1H), 7.48 (d, J=4.0 Hz, 1H),
7.42–7.33 (m, 1H), 7.03 (d, J=8.7 Hz, 1H), 6.43 (t, J=5.6 Hz, 1H),
6.35 (dd, J=3.2, 1.8 Hz, 1H), 6.31 (d, J=3.3 Hz, 1H), 5.84–5.75 (m,
1H), 5.75–5.61 (m, 1H), 5.05 (hept, J=6.7 Hz, 1H), 4.64 (d,
J=5.4 Hz, 2H), 3.99 (s, 3H), 3.33 (dt, J=11.6, 5.8 Hz, 1H), 3.09–2.94
(m, 1H), 2.76 (t, J=6.0 Hz, 1H), 2.28–2.13 (m, 2H), 2.08–2.00 (m,
1H), 1.34 (d, J=6.6 Hz, 3H), 1.21 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.5, 162.0, 157.0, 153.2, 151.2,
143.7, 137.6, 128.2, 128.2, 127.1, 126.1, 126.1, 126.0, 126.0, 124.0,
122.7, 111.7, 110.7, 107.9, 56.0, 46.9, 37.0, 34.9, 31.2, 23.2, 22.4,
20.7, 20.4.
LC-MS (ESI): tR=5.08min, area: 97%, m/z 504 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C28H30N3O4S 504.1952, found
504.1927.
4.6.2.34. N-(2-Amino-2-oxoethyl)-5-(5-(cis-3-isopropyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)thiophene-2-
carboxamide (6e). This compound was prepared from 18 (114mg,
0.269mmol) and glycinamide.HCl (74mg, 0.67mmol) as described for
6a. The title compound was obtained as a white solid (88mg, 63%).
1H NMR (500MHz, CDCl3): δ 8.11 (d, J=2.2 Hz, 1H), 7.77 (dd,
J=8.7, 2.3 Hz, 1H), 7.62 (d, J=4.0 Hz, 1H), 7.49 (d, J=4.0 Hz, 1H),
7.24 (t, J=5.3 Hz, 2H), 7.02 (d, J=8.8 Hz, 1H), 6.61 (s, 1H),
5.85–5.75 (m, 2H), 5.71–5.65 (m, 1H), 5.04 (hept, J=6.7 Hz, 1H),
4.18 (d, J=5.1 Hz, 2H), 3.97 (s, 3H), 3.32 (dt, J=11.6, 5.8 Hz, 1H),
3.05–2.97 (m, 1H), 2.75 (t, J=6.0 Hz, 1H), 2.25–2.14 (m, 2H),
2.07–1.99 (m, 1H), 1.33 (d, J=6.6 Hz, 3H), 1.21 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 171.5, 166.5, 162.9, 157.0, 153.2,
144.2, 137.0, 128.7, 128.2, 127.2, 126.1, 126.0, 124.0, 122.6, 111.7,
56.0, 46.9, 43.4, 34.9, 31.2, 23.2, 22.5, 20.8, 20.4.
LC-MS (ESI): tR=4.19min, area: 95%, m/z 481 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C25H29N4O4 481.1904, found
481.1924.
4.6.2.35. cis-1-(5-(3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)azetidine-3-carbonitrile (19). To a solution of 17
(2.60 g, 6.89mmol) in dry toluene (15mL) was added Xantphos
(0.798 g, 1.38mmol), Pd(II)(OAc)2 (0.155 g, 0.689mmol), Cs2CO3
(4.49 g, 13.8mmol) and azetidine-3-carbonitrile.HCl (0.577 g,
6.89mmol). The mixture was stirred at 100 °C for 68 h. The reaction
mixture was filtered over celite with EtOAc (2×50mL). The filtrate
was washed with sat. aq. NH4Cl (2×25mL) and brine (20mL). The
organic phase was dried over MgSO4, filtered and concentrated in
vacuo. The residue was purified on a silica gel column eluting with
EtOAc/n-heptane (gradient, 5–40%) to afford 19 as a white solid
(1.21 g, 46%).
1H NMR (500MHz, CDCl3): δ 7.23 (dd, J=8.4, 2.1 Hz, 1H), 7.04
(d, J=2.1 Hz, 1H), 6.81 (d, J=8.4 Hz, 1H), 5.83–5.62 (m, 2H), 5.04
(hept, J=6.6 Hz, 1H), 4.29 (td, J=7.9, 4.2 Hz, 2H), 4.12 (td, J=7.2,
1.7 Hz, 2H), 3.85 (s, 3H), 3.61–3.51 (m, 1H), 3.28 (dt, J=11.5, 5.8 Hz,
1H), 3.05–2.96 (m, 1H), 2.72 (t, J=5.9 Hz, 1H), 2.25–2.10 (m, 2H),
2.06–1.96 (m, 1H), 1.32 (d, J=6.6 Hz, 3H), 1.20 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.5, 153.7, 151.0, 139.8, 128.2,
126.1, 124.1, 120.0, 119.1, 110.6, 110.2, 56.7, 56.6, 55.7, 46.8, 34.8,
31.1, 23.3, 22.5, 20.7, 20.3, 19.1.
LC-MS (ESI): tR=4.45min, area:> 98%, m/z 379 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C22H27N4O2 379.2129, found
379.2128.
4.6.2.36. cis-1-(5-(3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)azetidine-3-carboxylic acid (20). A solution of 19
(1.05 g, 2.77mmol) in EtOH (2.7 mL) and aq. NaOH (1M, 2.7mL,
2.7 mmol) was stirred at 75 °C for 24 h. EtOAc (2× 10mL) was added
and the organic phase was washed with sat. aq. NH4Cl (2×10mL) and
brine (5mL). The combined organic phases were dried over MgSO4,
filtered and concentrated in vacuo to afford 20 as a white solid (0.55 g,
47%).
1H NMR (500MHz, DMSO-d6): δ 7.18 (d, J=8.3 Hz, 1H), 6.95–6.88
(m, 1H), 6.86 (d, J=8.5 Hz, 1H), 5.71–5.64 (m, 1H), 5.64–5.57 (m,
1H), 4.85 (hept, J=6.8 Hz, 1H), 4.06–3.94 (m, 2H), 3.92–3.85 (m,
2H), 3.73 (s, 3H), 3.37 (dt, J=11.6, 5.7 Hz, 1H), 3.31–3.25 (m, 1H),
2.80–2.65 (m, 2H), 2.23–2.10 (m, 1H), 2.10–2.01 (m, 1H), 1.84–1.72
(m, 1H), 1.21 (d, J=6.7 Hz, 3H), 1.11 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.0, 154.0, 150.4, 141.4, 127.5,
126.0, 124.2, 117.4, 111.0, 109.2, 56.5, 55.6, 45.7, 45.4, 34.0, 30.0,
22.9, 22.1, 20.5, 20.2.
LC-MS (ESI): tR=4.55min, area: 96%, m/z 398 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C22H28N3O4 398.2074, found
398.2060.
4.6.2.37. 1-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)azetidine-3-carboxamide (7a). This compound
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was prepared from 20 (110mg, 0.277mmol) and NH3 in MeOH (7M,
1.6 mL, 11mmol) as described for 6a. The title compound was obtained
as a white solid (63mg, 56%).
1H NMR (500MHz, DMSO-d6): δ 7.45 (s, 1H), 7.21 (dd, J=8.5,
2.1 Hz, 1H), 7.00 (s, 1H), 6.95–6.86 (m, 2H), 5.77–5.54 (m, 2H), 4.86
(hept, J=6.7 Hz, 1H), 4.00 (q, J=7.4 Hz, 2H), 3.84 (q, J=6.9 Hz,
2H), 3.76 (s, 3H), 3.42–3.37 (m, 2H), 2.81–2.67 (m, 2H), 2.22–2.02 (m,
2H), 1.85–1.74 (m, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.13 (d, J=6.8 Hz,
3H).
13C NMR (126MHz, DMSO-d6): δ 173.7, 166.0, 154.0, 150.4, 141.2,
127.5, 126.0, 124.2, 117.6, 111.0, 109.3, 55.9, 55.8, 55.6, 45.7, 34.3,
34.0, 30.0, 22.8, 22.0, 20.5, 20.2.
LC-MS (ESI): tR=4.13min, area:> 98%, m/z 397 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C22H29N4O3 397.2234, found
397.2216.
4.6.2.38. N-Butyl-1-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a-
hexahydrophthalazin-1-yl)-2-methoxyphenyl)azetidine-3-carboxamide
(7b). This compound was prepared from 20 (94.0mg, 0.236mmol)
and butan-1-amine (0.5 mL, 5.20mmol) as described for 6a. The title
compound was obtained as a white solid (34mg, 31%).
1H NMR (500MHz, DMSO-d6): δ 7.94 (t, J=5.6 Hz, 1H), 7.21 (dd,
J=8.4, 2.1 Hz, 1H), 6.99–6.84 (m, 2H), 5.74–5.57 (m, 2H), 4.86 (hept,
J=5.3 Hz, 1H), 4.01 (q, J=7.4 Hz, 2H), 3.83 (q, J=6.7 Hz, 2H), 3.76
(s, 3H), 3.46–3.38 (m, 2H), 3.05 (q, J=6.6 Hz, 2H), 2.82–2.67 (m, 2H),
2.21–2.02 (m, 2H), 1.86–1.74 (m, 1H), 1.37 (p, J=7.0 Hz, 2H),
1.32–1.18 (m, 5H), 1.12 (d, J=6.7 Hz, 3H), 0.86 (t, J=7.3 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 171.3, 166.0, 154.1, 150.4, 141.2,
127.5, 126.0, 124.2, 117.6, 111.1, 109.4, 55.9, 55.8, 55.6, 45.7, 38.3,
34.4, 34.0, 31.2, 30.0, 22.8, 22.0, 20.5, 20.2, 19.6, 13.8.
LC-MS (ESI): tR=5.02min, area:> 98%, m/z 453 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C26H37N4O3 453.2860, found
453.2846.
4.6.2.39. N-(Furan-2-ylmethyl)-1-(5-(cis-3-isopropyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)azetidine-3-
carboxamide (7c). This compound was prepared from 20 (110mg,
0.277mmol) and furan-2-ylmethanamine (0.06mL, 0.679mmol) as
described for 6a. The title compound was obtained as a white solid
(93mg, 64%).
1H NMR (500MHz, DMSO-d6): δ 8.47 (t, J=5.6 Hz, 1H), 7.58 (d,
J=1.4 Hz, 1H), 7.22 (dd, J=8.5, 2.2 Hz, 1H), 6.91 (d, J=2.1 Hz,
1H), 6.89 (d, J=8.5 Hz, 1H), 6.39 (dd, J=3.2, 1.9 Hz, 1H), 6.24 (d,
J=3.1 Hz, 1H), 5.72–5.66 (m, 1H), 5.66–5.58 (m, 1H), 4.86 (hept,
J=6.7 Hz, 1H), 4.28 (d, J=5.5 Hz, 2H), 4.02 (q, J=7.3 Hz, 2H), 3.86
(q, J=6.7 Hz, 2H), 3.76 (s, 3H), 3.47–3.38 (m, 2H), 2.79–2.69 (m, 2H),
2.21–2.02 (m, 2H), 1.85–1.74 (m, 1H), 1.23 (d, J=6.6 Hz, 3H), 1.13
(d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 171.5, 166.0, 154.0, 152.2, 150.4,
142.2, 141.1, 127.5, 126.0, 124.2, 117.6, 111.1, 110.5, 109.4, 107.0,
55.8, 55.7, 55.6, 45.7, 35.6, 34.3, 34.0, 30.0, 22.8, 22.0, 20.5, 20.2.
LC-MS (ESI): tR=4.85min, area: 97%, m/z 477 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C27H33N4O4 477.2496, found
477.2481.
4.6.2.40. N-(2-Amino-2-oxoethyl)-1-(5-(cis-3-isopropyl-4-oxo-
3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)azetidine-3-
carboxamide (7d). This compound was prepared from 20 (110mg,
0.277mmol) and glycinamide.HCl (76mg, 1.0 mmol) as described for
6a. The title compound was obtained as a white solid (90mg, 70%).
1H NMR (500MHz, DMSO-d6): δ 8.19 (t, J=5.9 Hz, 1H), 7.36 (s,
1H), 7.21 (dd, J=8.5, 2.1 Hz, 1H), 7.05 (s, 1H), 6.91 (d, J=2.1 Hz,
1H), 6.89 (d, J=8.5 Hz, 1H), 5.75–5.65 (m, 1H), 5.65–5.56 (m, 1H),
4.86 (hept, J=6.7 Hz, 1H), 4.02 (q, J=7.3 Hz, 2H), 3.86 (q,
J=6.7 Hz, 2H), 3.76 (s, 3H), 3.65 (d, J=5.8 Hz, 2H), 3.48 (p,
J=7.4 Hz, 1H), 3.41–3.36 (m, 4H), 2.79–2.68 (m, 2H), 2.22–2.02 (m,
2H), 1.86–1.73 (m, 1H), 1.23 (d, J=6.6 Hz, 3H), 1.13 (d, J=6.7 Hz,
3H).
13C NMR (126MHz, DMSO-d6): δ 172.0, 171.0, 166.0, 154.1, 150.4,
141.2, 127.5, 126.0, 124.2, 117.6, 111.0, 109.3, 55.9, 55.8, 55.6, 45.7,
42.0, 34.4, 34.0, 30.0, 22.9, 22.1, 20.5, 20.2.
LC-MS (ESI): tR=3.90min, area:> 98%, m/z 454 [M+H]+.
HRMS (ESI) m/z: [M+H]+ calcd. for C24H32N5O4 454.2449, found
454.2442.
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